Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors

Trial Profile

Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms VELDAY
  • Most Recent Events

    • 30 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Aug 2014 New trial record
    • 03 Jun 2014 Interim results (n=18) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top